Last reviewed · How we verify
ULTRACEF (CEFADROXIL/CEFADROXIL HEMIHYDRATE)
ULTRACEF (generic name: CEFADROXIL/CEFADROXIL HEMIHYDRATE) is a drug developed by BRISTOL. It is currently FDA-approved.
At a glance
| Generic name | CEFADROXIL/CEFADROXIL HEMIHYDRATE |
|---|---|
| Sponsor | BRISTOL |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil From Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated C (Phase 4)
- Oral vs Intravenous Antibiotics for Treatment of Periprosthetic Joint Infection (Phase 3)
- A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation (NA)
- A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers (Phase 1)
- Comparative Pharmacokinetics and Pharmacodynamics (PK/PD) of Cefadroxil and Cephalexin for Pediatric Musculoskeletal (MSK) Infections (Phase 1)
- BALANCE+: A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Antibiotics and Surgical Site Infection in Expander Based Breast Reconstruction Trial (ASSERT) A Multi-institutional Randomized Controlled Trial to Determine the Optimal Antibiotic Prophylaxis for Tis (NA)
- Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma) (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ULTRACEF CI brief — competitive landscape report
- ULTRACEF updates RSS · CI watch RSS
- BRISTOL portfolio CI
Frequently asked questions about ULTRACEF
What is ULTRACEF?
ULTRACEF (CEFADROXIL/CEFADROXIL HEMIHYDRATE) is a pharmaceutical drug developed by BRISTOL.
Who makes ULTRACEF?
ULTRACEF is developed and marketed by BRISTOL (see full BRISTOL pipeline at /company/bristol).
What is the generic name of ULTRACEF?
CEFADROXIL/CEFADROXIL HEMIHYDRATE is the generic (nonproprietary) name of ULTRACEF.
What development phase is ULTRACEF in?
ULTRACEF is FDA-approved (marketed).
Related
- Manufacturer: BRISTOL — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing